The use of major classes of drugs in the control of HF according to NYHA class is as follows:
Combination of an ACE inhibitor, an angiotensin receptor blocker and spirnolactone is not recommended since the safety and efficacy of combining these drugs is uncertain (1).
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.